List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. V-Motive: System for Comprehensive Therapy-Integrated Video Modeling

    SBC: EXPERIAD LLC            Topic: 104

    DESCRIPTIONprovided by applicantThis fast track SBIR will result in a new type of software systemcalled V Motivewhich will facilitate the combination of two proven autism behavioral interventionsApplied Behavior Analysis therapyABAand Video ModelingVMV Motive will have the potential to change how ABA therapy is performed by making it feasible for therapy providers to leverage VM in a comprehensive ...

    SBIR Phase II 2018 Department of Health and Human Services
  2. Therapy Management System for Model-Based Behavioral Interventions

    SBC: EXPERIAD LLC            Topic: 104

    In this Phase II SBIR applicationExperiad Solutions proposes to complete the development of Motivitya new type of software that has the potential to modernize the practice of behavioral therapy for autismApplied Behavior AnalysisABAis an evidence based autism treatment that is practiced by overBoard Certified Behavior AnalystsBCBAsin the USBCBAs analyze a child s unique needsthen construct an indi ...

    SBIR Phase II 2017 Department of Health and Human Services
  3. Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses

    SBC: Hawaii Biotech, Inc.            Topic: R

    DESCRIPTION provided by applicant The tick borne flavivirus TBFV group includes a number of important human pathogens that result in serious encephalitic or hemorrhagic diseases that are either Category B or C priority pathogens The TBFV are considered to be emerging or re emerging pathogens due to increases in the number of human cases the expansion of geographic distribution and emergen ...

    SBIR Phase II 2015 Department of Health and Human Services
  4. Heptax for Alcoholic Liver Disease

    SBC: CARDAX PHARMACEUTICALS, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) is caused by excessive long term consumption of alcohol via increased oxidative stress, reduction of oxygen to liver tissue (hypoxia), altered fat metabolism, increased pro-inflammatory signaling molecules (or cytokines), and increased inflammation. ALD begins with increased fat deposit in the liver. With continued excessive alcoho ...

    SBIR Phase II 2010 Department of Health and Human Services
  5. Recombinant Subunit Vaccine For Tick-Borne Encephalitis

    SBC: Hawaii Biotech, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Tick-borne encephalitis (TBE) is a neurological disease caused by Flaviviruses of the tick-borne encephalitis group and causes death in up to 60% of the individuals developing clinical symptoms. Survivors often show severe long-term neurological sequelae. In addition to the classical viruses, the TBE complex of viruses also contains members that cause hemorrha ...

    SBIR Phase II 2009 Department of Health and Human Services
  6. AUTOMATIC DELINEATION AND QUANTIFICATION OF WHITE MATTER SIGNAL HYPERINTENSITIES

    SBC: Neurobehavioral Research, Inc.            Topic: N/A

    Not Available

    SBIR Phase II 2008 Department of Health and Human Services
  7. MULTI-FOCAL CORTICAL THINNING IN DRUG AND ALCOHOL ABUSE

    SBC: Neurobehavioral Research, Inc.            Topic: N/A

    Not Available

    SBIR Phase II 2008 Department of Health and Human Services
  8. Inhibitors of Anthrax Lethal Factor Metalloproteinase

    SBC: PANTHERA BIOPHARMA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Anthrax Lethal Factor (LF) is a metalloproteinase introduced into the cells of mammalian hosts during infection by the bacterium Bacillus anthracis. LF disrupts intracellular signaling pathways mediated by the MAPKKs, resulting in cell toxicity, sepsis, respiratory failure and rapid death. While antibiotic therapy is effective if given in the first 48 h after s ...

    SBIR Phase II 2007 Department of Health and Human Services
  9. Recombinant Subunit Vaccine/Prevention of West Nile Vir*

    SBC: Hawaii Biotech, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): West Nile virus infection is an emerging infectious disease in the United States. The virus infects birds, which serve as the natural reservoir for the virus, in addition to humans and horses which are incidental h

    SBIR Phase II 2004 Department of Health and Human Services
  10. Development of a MSP1-p42 Subunit Vaccine for Malaria

    SBC: Hawaii Biotech, Inc.            Topic: N/A

    DESCRIPTION (provided by the applicant): Malaria is a tropical parasitic disease that poses a significant health threat to much of the world. Each year, approximately 500 million people become infected and more than 2 million die. There is a great need to control the spread of this disease. One of the main focuses of malaria vaccine development has been the on use o ...

    SBIR Phase II 2001 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government